Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3 -Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder.

@article{Yamaguchi2017PhaseIS,
  title={Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3 -Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder.},
  author={Osamu Yamaguchi and Yasushi Ikeda and Sumito Ohkawa},
  journal={Lower urinary tract symptoms},
  year={2017},
  volume={9 1},
  pages={38-45}
}
OBJECTIVES To investigate safety, tolerability and efficacy of long-term (52 weeks) open-label treatment with mirabegron 50 mg, with an optional dose increase to 100 mg, in patients with overactive bladder (OAB). METHODS Patients received mirabegron 50 mg once daily for 52 weeks. If efficacy was insufficient at week 8, the dose could be increased to 100 mg. Safety was evaluated based on vital signs, adverse events (AEs), laboratory findings, electrocardiogram and post-void residual volume… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Efficacy and safety of the selective β3-adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: double-blind, placebo-controlled, dose-finding study

O Yamaguchi, E Marui, M Takeda
LUTS 2015; • 2015

Clinical guidelines for overactive bladder.

International journal of urology : official journal of the Japanese Urological Association • 2009

Similar Papers

Loading similar papers…